CYP3A-Mediated Generation of Aldehyde and Hydrazine in Atazanavir Metabolism

被引:22
|
作者
Li, Feng [1 ]
Lu, Jie [1 ]
Wang, Laiyou [1 ]
Ma, Xiaochao [1 ]
机构
[1] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA
基金
美国国家卫生研究院;
关键词
HIV-INFECTION; DRUG; MECHANISMS; TOXICITY; BIOACTIVATION; PERSPECTIVE; MANAGEMENT; RITONAVIR; URINARY; FUTURE;
D O I
10.1124/dmd.110.036327
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Atazanavir (ATV) is an antiretroviral drug of the protease inhibitor class. Multiple adverse effects of ATV have been reported in clinical practice, such as jaundice, nausea, abdominal pain, and headache. The exact mechanisms of ATV-related adverse effects are unknown. It is generally accepted that a predominant pathway of drug-induced toxicity is through the generation of reactive metabolites. Our current study was designed to explore reactive metabolites of ATV. We used a metabolomic approach to profile ATV metabolism in mice and human liver microsomes. We identified 5 known and 13 novel ATV metabolites. Three potential reactive metabolites were detected and characterized for the first time: one aromatic aldehyde, one alpha-hydroxyaldehyde, and one hydrazine. These potential reactive metabolites were primarily generated by CYP3A. Our results provide a clue for studies on ATV-related adverse effects from the aspect of metabolic activation. Further studies are suggested to illustrate the impact of these potential reactive metabolites on ATV-related adverse effects.
引用
收藏
页码:394 / 401
页数:8
相关论文
共 50 条
  • [1] Intravenous diltiazem and CYP3A-mediated metabolism
    Masica, AL
    Azie, NE
    Brater, DC
    Hall, SD
    Jones, DR
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (03) : 273 - 276
  • [2] Effect of DHEA on CYP3A-mediated metabolism of triazolam.
    Frye, RF
    Kroboth, PD
    Folan, MM
    Kroboth, FJ
    von Moltke, LL
    Greenblatt, DJ
    Linares, AM
    Corey, SE
    Stone, R
    Pollock, BG
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 109 - 109
  • [3] Genetic contribution to variable human CYP3A-mediated metabolism
    Lamba, JK
    Lin, YS
    Schuetz, EG
    Thummel, KE
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (10) : 1271 - 1294
  • [4] Genetic contribution to variable human CYP3A-mediated metabolism
    Lamba, Jatinder K.
    Lin, Yvonne S.
    Schuetz, Erin G.
    Thummel, Kenneth E.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2012, 64 : 256 - 269
  • [5] Characterization of Maternal and Fetal CYP3A-Mediated Progesterone Metabolism
    Quinney, Sara K.
    Benjamin, Tara
    Zheng, Xiaomei
    Patil, Avinash S.
    [J]. FETAL AND PEDIATRIC PATHOLOGY, 2017, 36 (05) : 400 - 411
  • [6] In Vivo Inhibition of CYP3A-Mediated Midazolam Metabolism by Anchusan in Rats
    Saito, Yusuke
    Nishimura, Yuki
    Kurata, Norimitsu
    Iwase, Mariko
    Aoki, Kayo
    Yasuhara, Hajime
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 (03) : 399 - 407
  • [7] Inhibitory effect of anchusan on CYP3A-mediated drug metabolism in rats
    Saito, Yusuke
    Nishimura, Yuki
    Kurata, Norimitsu
    Iwase, Mariko
    Yasuhara, Hajime
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 167P - 167P
  • [8] In vitro hepatic metabolism of a CYP3A-mediated drug, quinine, in Adelie penguins
    Wanwimolruk, S
    Zhang, H
    Coville, PF
    Saville, DJ
    Davis, LS
    [J]. COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-PHARMACOLOGY TOXICOLOGY & ENDOCRINOLOGY, 1999, 124 (03): : 301 - 307
  • [9] The effect of tazemetostat on CYP3A-mediated metabolism of midazolam in patients with solid tumors
    Smith, Sherri
    Suttle, Benjamin
    Waters, Nigel L.
    Ribrag, Vincent
    Italiano, Antoine
    Michot, Jean-Marie
    Postel-Vinay, Sophie
    Toulmonde, Maud
    Cousin, Sophie
    Roche, Maria
    Pimentel, Patricia
    Ho, Peter
    [J]. CANCER RESEARCH, 2016, 76
  • [10] In vitro hepatic metabolism of CYP3A-mediated drug, quinine in the Antarctic Adelie penguins
    Wanwimolruk, S
    Zhang, H
    Coville, PF
    Saville, DJ
    Davis, LS
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R416 - R416